-
(
GoldhirschAWinerEPCoatesAS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol
2013; 24: 2206–2223.23917950)
GoldhirschAWinerEPCoatesAS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol
2013; 24: 2206–2223.23917950
GoldhirschAWinerEPCoatesAS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol
2013; 24: 2206–2223.23917950,
GoldhirschAWinerEPCoatesAS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol
2013; 24: 2206–2223.23917950
-
Audree
Tadros,
W.
Yang,
S.
Krishnamurthy,
G.
Rauch,
Benjamin
Smith,
V.
Valero,
D.
Black,
A.
Lucci,
A.
Caudle,
S.
DeSnyder,
M.
Teshome,
C.
Barcenas,
M.
Miggins,
B.
Adrada,
Tanya
Moseley,
R.
Hwang,
K.
Hunt,
H.
Kuerer
(2017)
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery
JAMA Surgery, 152
-
(
CortazarPZhangLUntchM, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560)
CortazarPZhangLUntchM, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560
CortazarPZhangLUntchM, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560,
CortazarPZhangLUntchM, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560
-
J.
Boughey,
L.
Mccall,
K.
Ballman,
E.
Mittendorf,
G.
Ahrendt,
L.
Wilke,
B.
Taback,
A.
Leitch,
T.
Flippo-Morton,
K.
Hunt
(2014)
Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
Annals of Surgery, 260
-
(
SrourMKTsengJLuuM, et al. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a National Cancer Database (NCDB) analysis. Ann Surg Oncol
2019; 26: 3305–3311.31342364)
SrourMKTsengJLuuM, et al. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a National Cancer Database (NCDB) analysis. Ann Surg Oncol
2019; 26: 3305–3311.31342364
SrourMKTsengJLuuM, et al. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a National Cancer Database (NCDB) analysis. Ann Surg Oncol
2019; 26: 3305–3311.31342364,
SrourMKTsengJLuuM, et al. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a National Cancer Database (NCDB) analysis. Ann Surg Oncol
2019; 26: 3305–3311.31342364
-
Q.
Wang-Lopez,
N.
Chalabi,
C.
Abrial,
N.
Radosevic-Robin,
X.
Durando,
M.
Mouret-Reynier,
K.
Benmammar,
S.
Kullab,
M.
Bahadoor,
P.
Chollet,
F.
Penault-Llorca,
J.
Nabholtz
(2015)
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Critical reviews in oncology/hematology, 95 1
-
(
SamieiSvan NijnattenTJAde MunckL, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg
2020; 271: 574–580.30557203)
SamieiSvan NijnattenTJAde MunckL, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg
2020; 271: 574–580.30557203
SamieiSvan NijnattenTJAde MunckL, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg
2020; 271: 574–580.30557203,
SamieiSvan NijnattenTJAde MunckL, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg
2020; 271: 574–580.30557203
-
(
SpringLGreenupRNiemierkoA, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. J Natl Compr Canc Netw
2017; 15: 1216–1223.28982747)
SpringLGreenupRNiemierkoA, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. J Natl Compr Canc Netw
2017; 15: 1216–1223.28982747
SpringLGreenupRNiemierkoA, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. J Natl Compr Canc Netw
2017; 15: 1216–1223.28982747,
SpringLGreenupRNiemierkoA, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. J Natl Compr Canc Netw
2017; 15: 1216–1223.28982747
-
(
TryfonidisKSenkusECardosoMJ, et al. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol
2015; 12: 147–162.25668732)
TryfonidisKSenkusECardosoMJ, et al. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol
2015; 12: 147–162.25668732
TryfonidisKSenkusECardosoMJ, et al. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol
2015; 12: 147–162.25668732,
TryfonidisKSenkusECardosoMJ, et al. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol
2015; 12: 147–162.25668732
-
(
MougalianSSHernandezMLeiX, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol
2016; 2: 508–516.26720612)
MougalianSSHernandezMLeiX, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol
2016; 2: 508–516.26720612
MougalianSSHernandezMLeiX, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol
2016; 2: 508–516.26720612,
MougalianSSHernandezMLeiX, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol
2016; 2: 508–516.26720612
-
Hee
Choi,
J.
Ryu,
Isaac
Kim,
S.
Nam,
S.
Kim,
Jonghan
Yu,
J.
Lee,
Se
Lee
(2019)
Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy
Breast Cancer Research and Treatment
-
N.
Houssami,
P.
Macaskill,
G.
Minckwitz,
M.
Marinovich,
E.
Mamounas
(2012)
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
European journal of cancer, 48 18
-
P.
Cortazar,
Lijun
Zhang,
M.
Untch,
K.
Mehta,
J.
Costantino,
N.
Wolmark,
H.
Bonnefoi,
D.
Cameron,
L.
Gianni,
P.
Valagussa,
S.
Swain,
Tatiana
Prowell,
S.
Loibl,
L.
Wickerham,
J.
Bogaerts,
J.
Baselga,
C.
Perou,
G.
Blumenthal,
J.
Blohmer,
E.
Mamounas,
J.
Bergh,
V.
Semiglazov,
R.
Justice,
H.
Eidtmann,
S.
Paik,
M.
Piccart,
R.
Sridhara,
P.
Fasching,
L.
Slaets,
Shenghui
Tang,
B.
Gerber,
C.
Geyer,
R.
Pazdur,
N.
Ditsch,
P.
Rastogi,
W.
Eiermann,
G.
Minckwitz
(2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
The Lancet, 384
-
M.
Pilewskie,
M.
Morrow
(2017)
Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review
JAMA Oncology, 3
-
(
van la ParraRFKuererHM.
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res
2016; 18: 28.26951131)
van la ParraRFKuererHM.
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res
2016; 18: 28.26951131
van la ParraRFKuererHM.
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res
2016; 18: 28.26951131,
van la ParraRFKuererHM.
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res
2016; 18: 28.26951131
-
(
PiltinMAHoskinTLDayCN, et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol
2020; 27: 4795–4801.32779055)
PiltinMAHoskinTLDayCN, et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol
2020; 27: 4795–4801.32779055
PiltinMAHoskinTLDayCN, et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol
2020; 27: 4795–4801.32779055,
PiltinMAHoskinTLDayCN, et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol
2020; 27: 4795–4801.32779055
-
(
TeeSRDevaneLAEvoyD, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg
2018; 105: 1541–1552.30311642)
TeeSRDevaneLAEvoyD, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg
2018; 105: 1541–1552.30311642
TeeSRDevaneLAEvoyD, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg
2018; 105: 1541–1552.30311642,
TeeSRDevaneLAEvoyD, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg
2018; 105: 1541–1552.30311642
-
H.
Kuerer,
G.
Rauch,
S.
Krishnamurthy,
B.
Adrada,
A.
Caudle,
S.
DeSnyder,
D.
Black,
L.
Santiago,
B.
Hobbs,
A.
Lucci,
M.
Gilcrease,
R.
Hwang,
R.
Candelaria,
M.
Chávez-MacGregor,
Benjamin
Smith,
E.
Arribas,
Tanya
Moseley,
M.
Teshome,
M.
Miggins,
V.
Valero,
K.
Hunt,
W.
Yang
(2017)
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy
Annals of Surgery, 267
-
A.
Goldhirsch,
E.
Winer,
A.
Coates,
R.
Gelber,
M.
Piccart-Gebhart,
B.
Thürlimann,
H.
Senn,
K.
Albain,
F.
André,
J.
Bergh,
H.
Bonnefoi,
Denisse
Bretel-Morales,
H.
Burstein,
F.
Cardoso,
M.
Castiglione‐Gertsch,
A.
Coates,
M.
Colleoni,
Alberto
Costa,
G.
Curigliano,
N.
Davidson,
A.
Leo,
B.
Ejlertsen,
J.
Forbes,
R.
Gelber,
M.
Gnant,
A.
Goldhirsch,
P.
Goodwin,
P.
Goss,
J.
Harris,
D.
Hayes,
C.
Hudis,
J.
Ingle,
J.
Jassem,
Zefei
Jiang,
P.
Karlsson,
S.
Loibl,
M.
Morrow,
M.
Namer,
C.
Osborne,
A.
Partridge,
F.
Penault-Llorca,
C.
Perou,
M.
Piccart-Gebhart,
K.
Pritchard,
E.
Rutgers,
F.
Sedlmayer,
V.
Semiglazov,
Z.
Shao,
I.
Smith,
B.
Thürlimann,
M.
Toi,
A.
Tutt,
M.
Untch,
G.
Viale,
Toru
Watanabe,
N.
Wilcken,
E.
Winer,
W.
Wood
(2013)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Annals of Oncology, 24
-
(
WongSMWeissAMittendorfEA, et al. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol
2019; 26: 3517–3525.31342389)
WongSMWeissAMittendorfEA, et al. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol
2019; 26: 3517–3525.31342389
WongSMWeissAMittendorfEA, et al. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol
2019; 26: 3517–3525.31342389,
WongSMWeissAMittendorfEA, et al. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol
2019; 26: 3517–3525.31342389
-
K.
Broglio,
M.
Quintana,
M.
Foster,
Melissa
Olinger,
A.
McGlothlin,
S.
Berry,
J.
Boileau,
C.
Brezden-Masley,
S.
Chia,
S.
Dent,
K.
Gelmon,
A.
Paterson,
D.
Rayson,
D.
Berry
(2016)
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
JAMA oncology, 2 6
-
G.
Minckwitz,
M.
Untch,
J.
Blohmer,
S.
Costa,
H.
Eidtmann,
P.
Fasching,
B.
Gerber,
W.
Eiermann,
J.
Hilfrich,
J.
Huober,
C.
Jackisch,
M.
Kaufmann,
G.
Konecny,
C.
Denkert,
V.
Nekljudova,
K.
Mehta,
S.
Loibl
(2012)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
-
(2013)
Neo - adjuvant chemotherapy and axillary deescalation management for patients with clinically node - negative breast cancer
-
(
TadrosABYangWTKrishnamurthyS, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg
2017; 152: 665–670.28423171)
TadrosABYangWTKrishnamurthyS, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg
2017; 152: 665–670.28423171
TadrosABYangWTKrishnamurthyS, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg
2017; 152: 665–670.28423171,
TadrosABYangWTKrishnamurthyS, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg
2017; 152: 665–670.28423171
-
(
PilewskieMMorrowM.
Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol
2017; 3: 549–555.27918753)
PilewskieMMorrowM.
Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol
2017; 3: 549–555.27918753
PilewskieMMorrowM.
Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol
2017; 3: 549–555.27918753,
PilewskieMMorrowM.
Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol
2017; 3: 549–555.27918753
-
(
Al-HilliZHoskinTLDayCN, et al. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol
2018; 25: 482–493.29181679)
Al-HilliZHoskinTLDayCN, et al. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol
2018; 25: 482–493.29181679
Al-HilliZHoskinTLDayCN, et al. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol
2018; 25: 482–493.29181679,
Al-HilliZHoskinTLDayCN, et al. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol
2018; 25: 482–493.29181679
-
A.
Schneeweiss,
S.
Chia,
T.
Hickish,
Vernon
Harvey,
A.
Eniu,
R.
Hegg,
C.
Tausch,
J.
Seo,
Y.
Tsai,
J.
Ratnayake,
V.
Mcnally,
G.
Ross,
J.
Cortés
(2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
-
(
GoortsBvan NijnattenTJde MunckL, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat
2017; 163: 83–91.28205044)
GoortsBvan NijnattenTJde MunckL, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat
2017; 163: 83–91.28205044
GoortsBvan NijnattenTJde MunckL, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat
2017; 163: 83–91.28205044,
GoortsBvan NijnattenTJde MunckL, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat
2017; 163: 83–91.28205044
-
R.
Parra,
H.
Kuerer
(2016)
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials
Breast Cancer Research : BCR, 18
-
T.
Kuehn,
I.
Bauerfeind,
T.
Fehm,
B.
Fleige,
M.
Hausschild,
G.
Helms,
A.
Lebeau,
C.
Liedtke,
G.
Minckwitz,
V.
Nekljudova,
S.
Schmatloch,
P.
Schrenk,
A.
Staebler,
M.
Untch
(2013)
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
The Lancet. Oncology, 14 7
-
B.
Goorts,
T.
Nijnatten,
L.
Munck,
M.
Moossdorff,
E.
Heuts,
M.
Boer,
M.
Lobbes,
M.
Smidt
(2017)
Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
Breast Cancer Research and Treatment, 163
-
Marissa
Srour,
J.
Tseng,
M.
Luu,
R.
Alban,
A.
Giuliano,
A.
Chung
(2019)
Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis
Annals of Surgical Oncology, 26
-
Alison
Barron,
T.
Hoskin,
C.
Day,
E.
Hwang,
H.
Kuerer,
J.
Boughey
(2018)
Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy
JAMA Surgery, 153
-
(
HoussamiNMacaskillPvon MinckwitzG, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer
2012; 48: 3342–3354.22766518)
HoussamiNMacaskillPvon MinckwitzG, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer
2012; 48: 3342–3354.22766518
HoussamiNMacaskillPvon MinckwitzG, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer
2012; 48: 3342–3354.22766518,
HoussamiNMacaskillPvon MinckwitzG, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer
2012; 48: 3342–3354.22766518
-
S.
Mougalian,
Mike
Hernandez,
X.
Lei,
S.
Lynch,
H.
Kuerer,
W.
Symmans,
R.
Theriault,
B.
Fornage,
L.
Hsu,
T.
Buchholz,
A.
Sahin,
K.
Hunt,
W.
Yang,
G.
Hortobagyi,
V.
Valero
(2016)
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.
JAMA oncology, 2 4
-
N.
Harbeck,
O.
Gluz
(2017)
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
Breast, 34 Suppl 1
-
Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer
-
(
SchneeweissAChiaSHickishT, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196)
SchneeweissAChiaSHickishT, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196
SchneeweissAChiaSHickishT, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196,
SchneeweissAChiaSHickishT, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196
-
(
BarronAUHoskinTLDayCN, et al. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg
2018; 153: 1120–1126.30193375)
BarronAUHoskinTLDayCN, et al. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg
2018; 153: 1120–1126.30193375
BarronAUHoskinTLDayCN, et al. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg
2018; 153: 1120–1126.30193375,
BarronAUHoskinTLDayCN, et al. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg
2018; 153: 1120–1126.30193375
-
Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study
-
S.
Wong,
A.
Weiss,
E.
Mittendorf,
T.
King,
M.
Golshan
(2019)
Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis
Annals of Surgical Oncology, 26
-
Z.
Al‐Hilli,
T.
Hoskin,
C.
Day,
E.
Habermann,
J.
Boughey
(2018)
Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype
Annals of Surgical Oncology, 25
-
(
BroglioKRQuintanaMFosterM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol
2016; 2: 751–760.26914222)
BroglioKRQuintanaMFosterM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol
2016; 2: 751–760.26914222
BroglioKRQuintanaMFosterM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol
2016; 2: 751–760.26914222,
BroglioKRQuintanaMFosterM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol
2016; 2: 751–760.26914222
-
S.
Samiei,
T.
Nijnatten,
L.
Munck,
K.
Keymeulen,
J.
Simons,
L.
Kooreman,
S.
Siesling,
M.
Lobbes,
M.
Smidt
(2020)
Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy.
Annals of surgery
-
E.
Mamounas
(2015)
Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer
Annals of Surgical Oncology, 22
-
(
RastogiPAndersonSJBearHD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986)
RastogiPAndersonSJBearHD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986
RastogiPAndersonSJBearHD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986,
RastogiPAndersonSJBearHD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986
-
(
MamounasEP.
Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol
2015; 22: 1425–1433.25727558)
MamounasEP.
Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol
2015; 22: 1425–1433.25727558
MamounasEP.
Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol
2015; 22: 1425–1433.25727558,
MamounasEP.
Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol
2015; 22: 1425–1433.25727558
-
(
ClasseJMBordesVCampionL, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol
2009; 27: 726–732.19114697)
ClasseJMBordesVCampionL, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol
2009; 27: 726–732.19114697
ClasseJMBordesVCampionL, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol
2009; 27: 726–732.19114697,
ClasseJMBordesVCampionL, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol
2009; 27: 726–732.19114697
-
(
KuehnTBauerfeindIFehmT, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol
2013; 14: 609–618.23683750)
KuehnTBauerfeindIFehmT, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol
2013; 14: 609–618.23683750
KuehnTBauerfeindIFehmT, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol
2013; 14: 609–618.23683750,
KuehnTBauerfeindIFehmT, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol
2013; 14: 609–618.23683750
-
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer
-
M.
Piltin,
T.
Hoskin,
C.
Day,
John
Davis,
J.
Boughey
(2020)
Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
Annals of Surgical Oncology, 27
-
J.
Boileau,
B.
Poirier,
M.
Basik,
C.
Holloway,
L.
Gaboury,
L.
Sidéris,
S.
Meterissian,
A.
Arnaout,
M.
Brackstone,
D.
McCready,
S.
Karp,
I.
Trop,
A.
Lisbona,
F.
Wright,
R.
Younan,
L.
Provencher,
E.
Patocskai,
A.
Omeroglu,
A.
Robidoux
(2015)
Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 3
-
(
BougheyJCMcCallLMBallmanKV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg
2014; 260: 608–614 and 614–606.)
BougheyJCMcCallLMBallmanKV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg
2014; 260: 608–614 and 614–606.
BougheyJCMcCallLMBallmanKV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg
2014; 260: 608–614 and 614–606.,
BougheyJCMcCallLMBallmanKV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg
2014; 260: 608–614 and 614–606.
-
(
BougheyJC.
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. JAMA
2013; 310: 1455–1461.24101169)
BougheyJC.
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. JAMA
2013; 310: 1455–1461.24101169
BougheyJC.
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. JAMA
2013; 310: 1455–1461.24101169,
BougheyJC.
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. JAMA
2013; 310: 1455–1461.24101169
-
Laura
Spring,
R.
Greenup,
A.
Niemierko,
L.
Schapira,
Stephanie
Haddad,
R.
Jimenez,
S.
Coopey,
A.
Taghian,
K.
Hughes,
S.
Isakoff,
L.
Ellisen,
Barbara
Smith,
M.
Specht,
B.
Moy,
A.
Bardia
(2017)
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN, 15 10
-
(
KuererHMRauchGMKrishnamurthyS, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg
2018; 267: 946–951.28549010)
KuererHMRauchGMKrishnamurthyS, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg
2018; 267: 946–951.28549010
KuererHMRauchGMKrishnamurthyS, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg
2018; 267: 946–951.28549010,
KuererHMRauchGMKrishnamurthyS, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg
2018; 267: 946–951.28549010
-
K.
Tryfonidis,
E.
Senkus,
M.
Cardoso,
F.
Cardoso
(2015)
Management of locally advanced breast cancer—perspectives and future directions
Nature Reviews Clinical Oncology, 12
-
(
von MinckwitzGUntchMBlohmerJU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol
2012; 30: 1796–1804.22508812)
von MinckwitzGUntchMBlohmerJU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol
2012; 30: 1796–1804.22508812
von MinckwitzGUntchMBlohmerJU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol
2012; 30: 1796–1804.22508812,
von MinckwitzGUntchMBlohmerJU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol
2012; 30: 1796–1804.22508812
-
(
TanVKGohBKFook-ChongS, et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer–a systematic review and meta-analysis. J Surg Oncol
2011; 104: 97–103.21456092)
TanVKGohBKFook-ChongS, et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer–a systematic review and meta-analysis. J Surg Oncol
2011; 104: 97–103.21456092
TanVKGohBKFook-ChongS, et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer–a systematic review and meta-analysis. J Surg Oncol
2011; 104: 97–103.21456092,
TanVKGohBKFook-ChongS, et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer–a systematic review and meta-analysis. J Surg Oncol
2011; 104: 97–103.21456092
-
P.
Rastogi,
S.
Anderson,
H.
Bear,
C.
Geyer,
M.
Kahlenberg,
A.
Robidoux,
R.
Margolese,
J.
Hoehn,
V.
Vogel,
S.
Dakhil,
D.
Tamkus,
K.
King,
E.
Pajon,
Mary
Wright,
J.
Robert,
S.
Paik,
E.
Mamounas,
N.
Wolmark
(2008)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
-
(
ChoiHJRyuJMKimI, et al. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat
2019; 176: 591–596.31065874)
ChoiHJRyuJMKimI, et al. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat
2019; 176: 591–596.31065874
ChoiHJRyuJMKimI, et al. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat
2019; 176: 591–596.31065874,
ChoiHJRyuJMKimI, et al. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat
2019; 176: 591–596.31065874
-
V.
Tan,
B.
Goh,
S.
Fook-Chong,
L.
Khin,
W.
Wong,
W.
Yong
(2011)
The feasibility and accuracy of sentinel lymph node biopsy in clinically node‐negative patients after neoadjuvant chemotherapy for breast cancer—a systematic review and meta‐analysis
Journal of Surgical Oncology, 104
-
(
BoileauJFPoirierBBasikM, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol
2015; 33: 258–264.25452445)
BoileauJFPoirierBBasikM, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol
2015; 33: 258–264.25452445
BoileauJFPoirierBBasikM, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol
2015; 33: 258–264.25452445,
BoileauJFPoirierBBasikM, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol
2015; 33: 258–264.25452445
-
(
Wang-LopezQChalabiNAbrialC, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Crit Rev Oncol Hematol
2015; 95: 88–104.25900915)
Wang-LopezQChalabiNAbrialC, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Crit Rev Oncol Hematol
2015; 95: 88–104.25900915
Wang-LopezQChalabiNAbrialC, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Crit Rev Oncol Hematol
2015; 95: 88–104.25900915,
Wang-LopezQChalabiNAbrialC, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Crit Rev Oncol Hematol
2015; 95: 88–104.25900915
-
(
HarbeckNGluzO.
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast
2017; 34: S99–S103.)
HarbeckNGluzO.
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast
2017; 34: S99–S103.
HarbeckNGluzO.
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast
2017; 34: S99–S103.,
HarbeckNGluzO.
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast
2017; 34: S99–S103.
-
(
ShiZqQiuPfLiuYb, et al. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. Breast Journal
2019; 25: 1154–1159.)
ShiZqQiuPfLiuYb, et al. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. Breast Journal
2019; 25: 1154–1159.
ShiZqQiuPfLiuYb, et al. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. Breast Journal
2019; 25: 1154–1159.,
ShiZqQiuPfLiuYb, et al. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. Breast Journal
2019; 25: 1154–1159.